Michael Grant

med onc/ hematologist at @yalecancer | thoracic ca. | asst. professor @yalemed | alum @imresidencyduke, @yalehemonc

[Michael Grant @MJGrantMD]

#LCSM

[Yale Cancer Center @YaleCancer]

.@DrRoyHerbstYale @politikaterina @MJGrantMD provide insight #ASCODailyNews on the Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer #NSCLC #lcsm @ASCO @SmilowCancer @YaleMed @YNHH https://t.co/G5HAyioPfP

[Paul Stockhammer @StockhammerPaul]

Great to see our work on #HER2 mutations in #HER2 mutant #LungCancer out in print in @JTOonline.
doi: 10.1016/j.jtho.2026.103708

💡We show that there is ⬆️ clinicogenomic variability among patients with #NSCLC tumors harboring different #HER2 activating mutations. 🫁

[Alessandro Di Federico @DiFedericoMD]

A brief recap of our FRONT-BRAF study, retrospectively comparing immunotherapy +/- chemotherapy to BRAF+MEK inhibitors for the first-line treatment of patients with stage IV, BRAF V600E-mutated NSCLC

https://t.co/ijbh8g3iwk

@BRicciutiMD @MDAndersonNews @MSKCancerCenter

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

🚨🔥The future of #ThoracicOncology 🫁is SO BRIGHT!

I’m honored, along with my great co-chair, @ChristianRolfo, AMAZING faculty mentors & #IASLC staff to kick off the:

"2025 global @IASLC #Academy”

Welcome to an OUTSTANDING group of
#EarlyCareer #Physicians & #Researchers.

[Gavitt Woodard @GavittWoodard]

Thanks @JTOonline for the opportunity to comment on this important topic. Strong data support 🫁 screening in smokers but I don't think we are ready to expand criteria to low-risk patients without more data on their survival benefit.

More thoughts here:
https://t.co/pro7yYa8CA

[Talal El Zarif, MD @TalalZarif1]

Enjoyed sharing our work on ERBB2 mutations in Lung Cancer with a Merit Award from @ConquerCancerFd! Thanks to @StockhammerPaul for spearheading this effort, @MJGrantMD @politikaterina #SarahGoldberg for the immense mentorship and to @TradIMYale for their support! #ASCO24

[David Gandara @drgandara]

Yes, Alina trial changes SOC in resected ALK+ NSCLC. Remarkable that result achieved without chemotherapy.

[Michael Grant @MJGrantMD]

@esinghimd @LungsRLife @maraantonoff @MDAndersonNews @YoungLungCancer @WomenInThoracic @LungCancerRx Congrats. Look forward to seeing your work help this population!

[Timil Patel, MD @timilpatel]

In NSCLC IO trials, the moderate link between ORR & PFS and OS necessitates thorough OS analyses, even if initial PFS results are not promising. This critical measure ensures potential survival benefits are not overlooked. @lobo_goulart @harpreet_md @FDAOncology

[Michael Grant @MJGrantMD]

Beyond the EGFR mutations in EGFR mutant lung cancer @StockhammerPaul

[JTO & JTO CRR @JTOonline]

To provide a more detailed analysis of TKIs' impact on pts w/EGFRmut #NSCLC, authors found that pts w/TP53mut/TSGmut tumors have an aggressive disease phenotype & inferior outcomes on EGFR TKIs, implying that some pts would benefit from add. therapy types. https://t.co/A1xSgmq0d5

[Eric K. Singhi, MD @lungoncdoc]

“Approximately half of the patients who experience disease progression s/p definitive CCRT & IO per PACIFIC regimen have low-volume relapse or oligometastatic relapse & therefore are candidates for further potentially curative-intent ablative therapy.”

@IASLC @OncoAlert #lcsm

[Paul Stockhammer @StockhammerPaul]

Excited to share our recent work now published in
@JTOonline:
👉Pts with #EGFR mt NSCLC with co-mut in TP53 and another suppressor gene have ⬆️aggressive dz and ⬇️outcomes on TKIs.
👉These findings may help to identify pts for Tx strategies beyond Osi.
https://t.co/oGYN4kaI4s

[Lilly Oncology Medical @LillyOncMed]

At #EHA2023 - Learn about the genomic evolution & resistance to a highly selective, non-covalent (reversible) BTK inhibitor in patients with CLL that were previously treated with a covalent BTK inhibitor (cBTKi). #leusm #lymsm

See the details here: https://t.co/oeF3fV7Q8x

[Annals of Oncology @Annals_Oncology]

IMscin001 (NCT03735121) was a randomized phase III trial investigating anti-PDL1 MoAb Atezolizumab as a SC formulation 💉 in NSCLC 🫁

Results of this non-inferiority study are now available #openaccess in Annals of Oncology:
https://t.co/7cwpsqdizg #lcsm

[Michael Grant @MJGrantMD]

@AminNassarMD @TheLancet Amazing work taking on an important challenging topic

[Amin Nassar, MD @AminNassarMD]

So fortunate to share our @TheLancet preprint. This is proof-of-concept showing that unanswered clinical questions in rare diseases can be accomplished by global collaboration across tens of centers! TOOK A VILLAGE to answer this and hopefully more similar efforts to come.

[Marlowe S Tessmer @Marlowe_Tessmer]

Hot off the press @CCR_AACR @YaleMed @YaleCancer
Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations https://t.co/99x9om1qp9

[Stephen V Liu, MD @StephenVLiu]

Survival benefit in ADAURA: adjuvant osimertinib for resected #EGFR NSCLC hits secondary endpoint of overall survival. For those not convinced by the profound DFS benefit (HR 0.23 in stage II/IIIA), we now have OS data. @FordePatrick @DrSteveMartin

https://t.co/08uMa4GHVg

[Michael Grant @MJGrantMD]

@StockhammerPaul @EGFRSummit @EGFRResisters @politikaterina @YaleIMed @YaleCancer @MarkDSiegel1 Congrats Paul Glad you were able to share your work at @EGFRSummit. Great community and great conference.

[Qasim Hussaini, MD @QasimHussainiMD]

Out today in @BloodAdvances, we show stark disparities in access to end-of-life care for individuals with hematologic malignancies living in Rural America

Our findings and thoughts on this important, nuanced & policy-relevant topic below. We can do better https://t.co/n0K6XDEYCs